Physician profile
Sunil Thomas
NPI 1427362698
$3,448.53
in general payments reported to CMS, 2019-2025
25 companies · $2,157 in 2025
The $2,157 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $41.80 · 2021: $141 · 2022: $200 · 2023: $58.53 · 2024: $684 · 2025: $2,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $577.74 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $444.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Insulet Corporation | $346.50 | 2020-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $336.96 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $219.48 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $209.59 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $161.37 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $155.98 | 2022-2025 | Mounjaro, Zepbound |
| Antares Pharma, INC. | $147.93 | 2024-2025 | Xyosted |
| Mannkind Corporation | $118.80 | 2022 | |
| Amneal Pharmaceuticals LLC | $103.33 | 2025 | Unithroid |
| Madrigal Pharmaceuticals | $90.47 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $69.83 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $65.68 | 2021-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $55.82 | 2025 | Isturisa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $53.25 | 2019-2025 | Korlym |
| Medtronic Minimed, INC. | $49.96 | 2019-2020 | |
| Intra-Sana Laboratories | $40.47 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Sequel Med Tech, LLC | $39.54 | 2025 | Twiist |
| Cequr Corporation | $38.67 | 2024-2025 | Cequr Simplicity |
| Progenics Pharmaceuticals, INC. | $34.91 | 2019 | |
| Boston Scientific Corporation | $30.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.71 | 2025 | |
| Radius Health, INC. | $17.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.